Mode
Text Size
Log in / Sign up
N/A N=20 Randomized Prevention

Pharmacokinetic Alterations During ECMO

Acute Respiratory Failure

Enrolled (actual)
20
Serious AEs
0.0%
Results posted
Sep 2016
Primary outcome: Primary: Cumulative Fentanyl Equivalents From ECMO Initiation to Decision to Achieve Wakefulness — 330; 834 mg

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
Ketamine (Drug); Sedative drug regimen (Other)
Age
Adult, Older Adult · 18+ yrs
Sex
All
Sponsor
Columbia University
Primary completion
Feb 2015

Outcome Measures

OutcomeResultp-value
PRIMARY
Cumulative Fentanyl Equivalents From ECMO Initiation to Decision to Achieve Wakefulness
330; 834

Summary

In a healthy patient, the lungs provide oxygen to the blood and remove carbon dioxide. However, in patients with severe lung failure, blood may not adequately be delivered to the lungs, or the lungs may not adequately supply blood with oxygen. In this case, patients may require assistance from a machine to help provide this oxygen. Extracorporeal membrane oxygenation (ECMO) is a device that acts as an artificial lung, allowing the patient to recover from their illness. Patients receiving support from ECMO are often put in a medically induced coma while their lungs heal. Certain drugs may stick to the internal surfaces of the machine; therefore leading to decreased concentrations. Patients receiving ECMO often require high doses of both pain medications and sedatives in order to provide comfort. Low doses of a drug, ketamine, may help to provide additive effects to pain relief and allow lower doses of other pain medications. The hypothesis is that patients treated with continuous intravenous ketamine, will have lower requirements of other pain medications while receiving ECMO for acute respiratory failure while achieving the desired level of sedation.

Eligibility Criteria

Inclusion Criteria

  • Receiving ECMO for acute respiratory failure
  • Requiring deep sedation (RASS -5)

Exclusion Criteria

  • Allergy to ketamine
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT01938079). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search